A Systematic Review of Health-Related Quality of Life Outcomes in Patients With Advanced Breast Cancer Treated With Palbociclib

The systematic review assessed the impact of palbociclib on health-related quality of life (HRQoL) in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, incorporating data from 15 studies, including randomized controlled trials and real-world evidence. The findings indicate that palbociclib generally maintains or improves HRQoL, particularly in areas like physical functioning and pain, while some side effects, such as hair loss, may negatively impact specific aspects of quality of life. The review highlights the importance of HRQoL assessments in treatment evaluation, showing that palbociclib provides clinical benefits without compromising overall HRQoL, even in diverse and often underrepresented patient populations.